Bone marrow mononuclear cell transplantation had beneficial effects on doxorubicin-induced cardiomyopathy

Ishida, Michiko; Tomita, Shinji; Nakatani, Takeshi; Fukuhara, Shinya; Hamamoto, Masaki; Nagaya, Noritoshi; Ohtsu, Yoshinori; Suga, Michiharu; Yutani, Chikao; Yagihara, Toshikatsu; Yamada, Kazulliko; Kitamura, Soichiro

doi:10.1016/s1053-2498(03)00220-1

Cited by 39 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent evidence from work using bone marrow mononuclear cells (BMMNC) to treat myocardial infarction has shown a robust proangiogenic and antifibrotic effect of exogenous BMMNC therapy in ischemic hearts (8). Similar remodeling benefits have also been observed in models of myocarditis and dilated cardiomyopathy (11,27) and in pressure-overload caused by aortic banding (25). There are currently no studies that have examined specific benefits of BMMNC administration to prevent or reverse diastolic dysfunction during the complex systemic condition of hypertension.…”

mentioning

confidence: 93%

Bone marrow mononuclear cells induce beneficial remodeling and reduce diastolic dysfunction in the left ventricle of hypertensive SS/MCWi rats

Parker

Didier

Karcher

et al. 2012

Physiological Genomics

View full text Add to dashboard Cite

Little is known about the effectiveness of BMMNC therapy in hypertensive heart disease. In the current study, we show that delivery of BMMNCs from hypertension protected SS-13 BN /MCWi donor rats, but not BMMNC from hypertension susceptible SS/MCWi donor rats, resulted in 57.2 and 83.4% reductions in perivascular and interstitial fibrosis, respectively, as well as a 60% increase in capillary-to-myocyte count in the left ventricles (LV) of hypertensive SS/MCWi recipients. These histological changes were associated with improvements in LV compliance and relaxation (103 and 46.4% improvements, respectively). Furthermore, improved diastolic function in hypertensive SS/MCWi rats receiving SS-13 BN /MCWi derived BMMNCs was associated with lower clinical indicators of heart failure, including reductions in end diastolic pressure (65%) and serum brain natriuretic peptide levels (49.9%) with no improvements observed in rats receiving SS/MCWi BMMNCs. SS/MCWi rats had a lower percentage of endothelial progenitor cells in their bone marrow relative to SS-13 BN /MCWi rats. These results suggest that administration of BMMNCs can prevent or reverse pathological remodeling in hypertensive heart disease, which contributes to ameliorating diastolic dysfunction and associated symptomology. Furthermore, the health and hypertension susceptibility of the BMMNC donor are important factors influencing therapeutic efficacy, possibly via differences in the cellular composition of bone marrow.

show abstract

mentioning

confidence: 93%

Bone marrow mononuclear cells induce beneficial remodeling and reduce diastolic dysfunction in the left ventricle of hypertensive SS/MCWi rats

Parker

Didier

Karcher

et al. 2012

Physiological Genomics

View full text Add to dashboard Cite

show abstract

“…Cell transplantation is a promising therapy for end-stage heart failure. Its feasibility and efficiency have been proven in ischemic cardiomyopathy [6][7][8][9][10][11] and may also offer a new hope for non-ischemic DCM [12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Granulocyte Colony-Stimulating Factor Reduces Cardiomyocyte Apoptosis and Improves Cardiac Function in Adriamycin-Induced Cardiomyopathy in Rats

Son

Wang

et al. 2006

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

“…Monnet and Orton [25] demonstrated in a similar trial that dynamic cardiomyoplasty reduced myocardial oxygen consumption but did not lower overall cardiac work. [20,40] Level II C Experimental cell transplantation [42,43] Level II C Cardiac transplantation [45][46][47] Level III D Left ventricular assist devices [48,50] Level Furthermore, this effect was also independent on skeletal muscle stimulation or not. Based on these two studies it seems questionable that dynamic cardiomyoplasty improves cardiac function in doxorubicin-induced heart failure.…”

Section: Experimental Surgical Proceduresmentioning

confidence: 99%

Doxorubicin in experimental and clinical heart failure

Christiansen

Autschbach

2006

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties. Prevention strategies have not demonstrated the expected success and unfortunately, this specific type of heart failure does not respond to the usual medical therapy as other kinds of heart failure. Therefore, surgical procedures may be necessary in some patients. Cardiac transplantation is performed in most cases but it requires the cure of the neoplastic disease. This usually requires a recurrence-free interval of several years which is associated with a high attrition rate in these patients due to their cardiac disease. Therefore, other conservative and surgical treatment concepts were developed during the last years. This review presents the most common procedures and discusses their efficacy as well as their clinical applicability.

show abstract

Bone marrow mononuclear cell transplantation had beneficial effects on doxorubicin-induced cardiomyopathy

Cited by 39 publications

References 15 publications

Bone marrow mononuclear cells induce beneficial remodeling and reduce diastolic dysfunction in the left ventricle of hypertensive SS/MCWi rats

Bone marrow mononuclear cells induce beneficial remodeling and reduce diastolic dysfunction in the left ventricle of hypertensive SS/MCWi rats

Granulocyte Colony-Stimulating Factor Reduces Cardiomyocyte Apoptosis and Improves Cardiac Function in Adriamycin-Induced Cardiomyopathy in Rats

Doxorubicin in experimental and clinical heart failure

Contact Info

Product

Resources

About